via Livemint.com
In a new study assessing the potential of a single-dose, intranasal COVID-19 vaccine, a team from the University of Iowa and the University of Georgia found that the vaccine fully protects mice against lethal COVID-19 infection. The vaccine also blocks animal-to-animal transmission of the virus.
The findings were published July 2 in the journal Science Advances.
“The currently available vaccines against COVID-19 are very successful, but the majority of the world’s population is still unvaccinated and there is a critical need for more vaccines that are easy to use and effective at stopping disease and transmission,” says Paul McCray, MD, professor of pediatrics-pulmonary medicine, and microbiology and immunology at the UI Carver College of Medicine, and co-leader of the study. “If this new COVID-19 vaccine proves effective in people, it may help block SARS-CoV-2 transmission and help control the COVID-19 pandemic.”
Unlike traditional vaccines that require an injection, this vaccine is administered through a nasal spray similar to those commonly used to vaccinate against influenza. The vaccine used in the study only requires a single dose and it may be stored at normal refrigerator temperatures for up to at least three months. Because it is given intranasally, the vaccine may also be easier to administer, especially for those who have a fear of needles.
“We have been developing this vaccine platform for more than 20 years, and we began working on new vaccine formulations to combat COVID-19 during the early days of the pandemic,” says Biao He, PhD, a professor in the University of Georgia’s Department of Infectious Diseases in the College of Veterinary Medicine and co-leader of the study. “Our preclinical data show that this vaccine not only protects against infection, but also significantly reduces the chances of transmission.”
The experimental vaccine uses a harmless parainfluenza virus 5 (PIV5) to deliver the SARS-CoV-2 spike protein into cells where it prompts an immune response that protects against COVID-19 infection. PIV5 is related to common cold viruses and easily infects different mammals, including humans, without causing significant disease. The research team has previously shown that this vaccine platform can completely protect experimental animals from another dangerous coronavirus disease called Middle Eastern Respiratory Syndrome (MERS).
The inhaled PIV5 vaccine developed by the team targets mucosal cells that line the nasal passages and airways. These cells are the main entry point for most SARS-CoV-2 infections and the site of early virus replication. Virus produced in these cells can invade deeper into the lungs and other organs in the body, which can lead to more severe disease. In addition, virus made in these cells can be easily shed through exhalation allowing transmission from one infected person to others.
Original Article: Inhaled COVID-19 vaccine prevents disease and transmission in animals
More from: University of Iowa | University of Georgia
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Inhalable Covid-19 vaccine
- US FDA pushes decision on Moderna's RSV vaccine to end of this month
May 10 (Reuters) - The U.S. Food and Drug Administration has pushed back its decision on Moderna's (MRNA.O) , opens new tab respiratory syncytial virus (RSV) vaccine by more than two weeks to the end ...
- Novavax, Sanofi Ink Deal to Commercialize COVID-19 Vaccine to Jointly Produce Combination Shots
Novavax, Inc., a biotechnology company headquartered in Gaithersburg, Maryland, revealed on Friday, May 10, that it has signed a licensing deal with Sanofi, a global healthcare company. The deal is ...
- Sanofi enters vaccine licensing deal with Novavax, giving beleaguered biotech a lifeline
Sanofi on Friday said it had reached a deal worth up to $1.2 billion to sell Novavax’s Covid shot as well as to try to combine the vaccine with its own flu shot.
- Sanofi Strikes COVID-19 Vaccine Agreement With Novavax; To Take Minority Stake
(RTTNews) - Sanofi (SNYNF, SNY) and Novavax Inc. (NVAX) announced a co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop Novel COVID-19-Influenza combination vaccines. In ...
- France's Sanofi in COVID-19 vaccine deal with Novavax
Sanofi on Friday announced it has reached a licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop new flu-COVID-19 combination vaccines while also taking an equity stake ...
Go deeper with Google Headlines on:
Inhalable Covid-19 vaccine
[google_news title=”” keyword=”inhalable Covid-19 vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Inhalable vaccines
- Oregon State Researchers Develop Innovative Device to Enhance Gene Therapy Delivery for Lung Disease Treatment
Drug delivery researchers at Oregon State University have developed a device with the potential to improve gene therapy for patients with inherited lung diseases such as cystic fibrosis.In cell ...
- COVID and SARS News
Apr. 1, 2024 — Researchers have developed a new vaccine that offers broad protection against not only SARS-CoV-2 variants, but also other bat sarbecoviruses. The groundbreaking trivalent vaccine ...
- The Evolving History of Influenza Viruses and Influenza Vaccines
Expert Rev Vaccines. 2013;12(9):1085-1094. It became obvious that it was necessary to modify regularly the composition of the vaccine, and that it was necessary to use vaccine strains selected ...
- China approves world’s first inhalable Covid-19 vaccine
Chinese drug regulators have approved the world’s first inhalable Covid-19 vaccine, made by Tianjin-based manufacturer Cansino Biologics. The National Medical Products Administration gave the go ...
- COVID-19 Vaccine Tracker
A guide to the coronavirus vaccination rollout and what you need to know about the authorized vaccines Some 63.8% of Americans have received both doses of the two-shot Pfizer-BioNTech and Moderna ...
Go deeper with Google Headlines on:
Inhalable vaccines
[google_news title=”” keyword=”inhalable vaccines” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]